Latest Pharma Insights
Impact Of China’s New Data Protection On Corporate Strategies, Deals
New data protection measures released by China’s drug regulator could influence future licensing deals for innovative assets originating in the country, particularly royalty terms, a law firm predicts.
Scrip - May 26, 2026
New data protection measures released by China’s drug regulator could influence future licensing deals for innovative assets originating in the country, particularly royalty terms, a law firm predicts.
Scrip - May 26, 2026
Review Of NAD+ Supplement Ad Claims Leaves Ingredient Pioneer Niagen ‘Deeply Disappointed’
BBB National Programs’ appeals board upholds National Advertising Division decision that Niagen Bioscience should discontinue or modify challenged ad claims for health benefits including heart, brain, immunity, metabolism and reproductive as well as anti-aging.
HBW Insight - May 26, 2026
BBB National Programs’ appeals board upholds National Advertising Division decision that Niagen Bioscience should discontinue or modify challenged ad claims for health benefits including heart, brain, immunity, metabolism and reproductive as well as anti-aging.
HBW Insight - May 26, 2026
Impact Of China’s New Data Protection On Corporate Strategies, Deals
New data protection measures released by China’s drug regulator could influence future licensing deals for innovative assets originating in the country, particularly royalty terms, a law firm predicts.
Scrip - May 26, 2026
New data protection measures released by China’s drug regulator could influence future licensing deals for innovative assets originating in the country, particularly royalty terms, a law firm predicts.
Scrip - May 26, 2026
QT Imaging CEO: AI Cannot Recover What Mammography Never Captured
The FDA's breast density rule reached 40 million women – but stopping at disclosure left a structural gap no technology has yet filled. QT Imaging's CEO explains why the real barriers are capacity, reimbursement and a screening system never built for what comes next.
Medtech Insight - May 25, 2026
The FDA's breast density rule reached 40 million women – but stopping at disclosure left a structural gap no technology has yet filled. QT Imaging's CEO explains why the real barriers are capacity, reimbursement and a screening system never built for what comes next.
Medtech Insight - May 25, 2026
Ebola Outbreak Drives Medical Device Makers to Mobilize PCR Tests and Blood-Filtration Technology
20/20 Biolabs, Co-Diagnostics and Aethlon mobilize PCR assays, lab capacity, and blood-filtration technology against the Bundibugyo strain, as world governments update their threat assessments and responses.
Medtech Insight - May 25, 2026
20/20 Biolabs, Co-Diagnostics and Aethlon mobilize PCR assays, lab capacity, and blood-filtration technology against the Bundibugyo strain, as world governments update their threat assessments and responses.
Medtech Insight - May 25, 2026
Review Of NAD+ Supplement Ad Claims Leaves Ingredient Pioneer Niagen ‘Deeply Disappointed’
BBB National Programs’ appeals board upholds National Advertising Division decision that Niagen Bioscience should discontinue or modify challenged ad claims for health benefits including heart, brain, immunity, metabolism and reproductive as well as anti-aging.
HBW Insight - May 26, 2026
BBB National Programs’ appeals board upholds National Advertising Division decision that Niagen Bioscience should discontinue or modify challenged ad claims for health benefits including heart, brain, immunity, metabolism and reproductive as well as anti-aging.
HBW Insight - May 26, 2026
MS Pharma Boosts Biosimilar Ambitions With Minority Equity Investment
Olayan Financing Company’s minority stake gives MS Pharma both the cash and the local network it needs to turn an ambitious MENA biosimilar strategy into real market presence in 2026.
Generics Bulletin - May 25, 2026
Olayan Financing Company’s minority stake gives MS Pharma both the cash and the local network it needs to turn an ambitious MENA biosimilar strategy into real market presence in 2026.
Generics Bulletin - May 25, 2026
Fresenius Celebrates US Federal Win On Ustekinumab
A federal contract in the US is set to bolster Fresenius Kabi’s Biopharma business, which grew by a quarter – and by 34% at constant currencies – in the first quarter of 2026, boosted by gains for tocilizumab and denosumab.
Generics Bulletin - May 25, 2026
A federal contract in the US is set to bolster Fresenius Kabi’s Biopharma business, which grew by a quarter – and by 34% at constant currencies – in the first quarter of 2026, boosted by gains for tocilizumab and denosumab.
Generics Bulletin - May 25, 2026
Accord’s Burden Moves Up To Chair At Medicines UK
UK generics and biosimilars association Medicines UK has announced the appointment of Accord’s Paul Burden as its new chair. He takes over the role from Sandoz’s Diane Di Gangi-Trench who will stay on for a further year as vice-chair.
Generics Bulletin - May 25, 2026
UK generics and biosimilars association Medicines UK has announced the appointment of Accord’s Paul Burden as its new chair. He takes over the role from Sandoz’s Diane Di Gangi-Trench who will stay on for a further year as vice-chair.
Generics Bulletin - May 25, 2026
MedTech Forum 2026 Interview: Bring The Innovation Launch Pad Back To Europe
MedTech Europe CEO Oliver Bisazza set out his hopes and aims for EU industry and markets during the MedTech Forum 2026 against a backdrop of cautious optimism in regulatory and strategy circles now the MDR/IVDR revision is getting EU co-legislator attention. Elsewhere, there remains work to do.
In Vivo - May 25, 2026
MedTech Europe CEO Oliver Bisazza set out his hopes and aims for EU industry and markets during the MedTech Forum 2026 against a backdrop of cautious optimism in regulatory and strategy circles now the MDR/IVDR revision is getting EU co-legislator attention. Elsewhere, there remains work to do.
In Vivo - May 25, 2026